Intensity Therapeutics, Inc. (INTS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the INTS SEC filings page.
This page shows Intensity Therapeutics, Inc. (INTS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The reported business is research-led: operating needs remain funded by financing, even as 2025 losses and cash use narrowed.
From FY2024 to FY2025, the operating loss narrowed by$4.6M as operating cash outflow narrowed by$6.0M . Their parallel movement points to spending reduction as the main improvement, not a shift toward cash generation, while financing remained necessary to fund the reduced cost base.
R&D was
Financing supplied
Financial Health Signals
Intensity Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Intensity Therapeutics, Inc. passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.
Intensity Therapeutics, Inc. reported a net loss of $11.6M while operations used $9.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Intensity Therapeutics, Inc. reported -$3.0M in net income in Q2 2026. This represents a decrease of 18.5% from the same quarter a year earlier. Against the prior quarter it is down 23.5%.
Intensity Therapeutics, Inc. earned -$1.11 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 15.6%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Intensity Therapeutics, Inc. held $9.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Intensity Therapeutics, Inc.'s ROE was -32.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 83.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.3 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Intensity Therapeutics, Inc. invested $1.8M in research and development in Q2 2026. This represents an increase of 18.9% from the same quarter a year earlier. Against the prior quarter it is up 53.4%.
Not reported for Q2 2026.
Not reported for Q2 2026.
INTS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.8M+18.9% | $1.2M-45.4% | N/A | $1.6M-27.8% | $1.5M-56.7% | $2.2M-22.2% | N/A | $2.2M+59.1% |
| SG&A Expenses | $1.3M+7.5% | $1.3M+10.5% | N/A | $1.2M-16.8% | $1.2M-22.7% | $1.2M-37.5% | N/A | $1.4M+24.6% |
| Operating Income | -$3.1M-14.0% | -$2.5M+25.6% | N/A | -$2.7M+23.4% | -$2.7M+46.6% | -$3.4M+28.4% | N/A | -$3.6M-43.3% |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Net Income | -$3.0M-18.5% | -$2.4M+27.3% | N/A | -$2.7M+24.0% | -$2.5M+49.0% | -$3.3M+27.3% | N/A | -$3.5M-50.8% |
| EPS (Basic) | -$1.11+67.0% | -$0.96+82.6% | -$8.23-3640.9% | -$0.06+76.0% | -$3.36-833.3% | -$5.51-1520.6% | -$0.22-83.3% | -$0.25-47.1% |
| EPS (Diluted) | -$1.11 | -$0.96 | -$8.23 | -$0.06 | -$3.36 | -$5.51 | -$0.22-83.3% | -$0.25-47.1% |
| Diluted Shares (Avg) | 3M | 3M | N/A | 43M | 754,725 | 606,928 | N/A | 14M+1.1% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.
INTS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.5M+159.3% | $12.3M+301.0% | $14.1M+194.8% | $9.6M+83.9% | $4.4M-48.8% | $3.1M-75.3% | $4.8M-72.3% | $5.2M-69.0% |
| Current Assets | $11.2M+269.6% | $10.9M+560.6% | $12.7M+277.9% | $8.2M+116.2% | $3.0M-59.2% | $1.7M-85.2% | $3.4M-78.3% | $3.8M-77.2% |
| Cash & Equivalents | $9.5M+330.0% | $10.2M+1002.8% | $11.9M+360.3% | $7.1M+154.0% | $2.2M-31.6% | $929K-87.5% | $2.6M-69.7% | $2.8M-58.4% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0-100.0% |
| Total Liabilities | $2.3M+2.1% | $2.3M-15.3% | $2.2M+19.3% | $2.4M-2.9% | $2.3M-32.1% | $2.7M+1.7% | $1.9M-54.9% | $2.4M+169.0% |
| Current Liabilities | $2.2M+3.7% | $2.2M-14.7% | $2.1M+22.3% | $2.3M-1.8% | $2.2M-32.5% | $2.6M+4.4% | $1.8M-55.7% | $2.3M+220.0% |
| Non-Current Liabilities | $62K-34.7% | $70K-31.4% | $79K-28.2% | $87K-25.6% | $95K-23.4% | $102K-38.9% | $110K-36.8% | $117K-35.3% |
| Total Equity | $9.2M+321.9% | $10.0M+2887.7% | $11.9M+307.0% | $7.2M+159.9% | $2.2M-59.1% | $334K-96.6% | $2.9M-77.8% | $2.8M-82.5% |
| Retained Earnings | -$83.8M-15.4% | -$80.8M-15.2% | -$78.4M-17.4% | -$75.3M-18.5% | -$72.7M-20.9% | -$70.1M-27.2% | -$66.8M-32.2% | -$63.6M-34.3% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
INTS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.3M+4.7% | -$1.8M+8.2% | -$2.4M+10.0% | -$2.4M+39.9% | -$2.5M+41.7% | -$2.0M+54.4% | -$2.7M-182.0% | -$4.0M+22.4% |
| Stock-Based Compensation | $387K-39.9% | $387K-11.0% | N/A | $471K-2.5% | $644K+9.0% | $435K-62.3% | N/A | $483K+37.6% |
| Investing Cash Flow | N/A | N/A | $0 | $0-100.0% | $0+100.0% | $0-100.0% | $0-100.0% | $3.1M+135.1% |
| Financing Cash Flow | $1.6M-56.6% | $150K-54.3% | $7.3M+193.0% | $7.2M+1652.5% | $3.7M+124666.7% | $328K+4000.0% | $2.5M+19146.2% | $413K-98.0% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
INTS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -32.6%+83.5pp | -24.4%+977.7pp | N/A | -37.0%+89.4pp | -116.2%-23.2pp | -1002.1%-954.8pp | N/A | -126.4%-111.8pp |
| Return on Assets | -26.1%+31.0pp | -19.8%+89.4pp | N/A | -27.9%+39.5pp | -57.1%+0.2pp | -109.2%-72.1pp | N/A | -67.4%-53.5pp |
| Current Ratio | 5.00+3.6x | 4.86+4.2x | 5.92+4.0x | 3.60+2.0x | 1.40-0.9x | 0.63-3.8x | 1.92-2.0x | 1.63-21.3x |
| Debt-to-Equity | 0.25-0.8x | 0.23-7.9x | 0.19-0.5x | 0.33-0.5x | 1.03+0.4x | 8.18+7.9x | 0.64+0.3x | 0.88+0.8x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Intensity Therapeutics, Inc. INTS | FY2025 | N/A | -$11.6M | N/A | $11.3M | — |
| Moleculin Biotech, Inc. MBRX | FY2025 | $0 | $33.6M | N/A | $9.9M | — |
| Ernexa Therapeutics Inc. ERNA | FY2025 | N/A | -$14.1M | N/A | $3.5M | — |
| LYRA THERAPEUTICS INC LYRA | FY2025 | $398K | -$28.9M | N/A | $2.3M | — |
| Sensei Biotherapeutics, Inc. SNSE | FY2025 | N/A | -$21.1M | N/A | $18.6M | — |
| Bolt Biotherapeutics, Inc. BOLT | FY2025 | $7.7M | -$33.4M | N/A | $6.6M | 64/100 |
Where Intensity Therapeutics, Inc. Ranks
Frequently Asked Questions
Is Intensity Therapeutics, Inc. profitable?
No, Intensity Therapeutics, Inc. (INTS) reported a net income of -$11.6M in fiscal year 2025.
What is Intensity Therapeutics, Inc.'s return on equity (ROE)?
Intensity Therapeutics, Inc. (INTS) has a return on equity of -97.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Intensity Therapeutics, Inc.'s operating cash flow?
Intensity Therapeutics, Inc. (INTS) recorded an outflow of $9.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Intensity Therapeutics, Inc.'s total assets?
Intensity Therapeutics, Inc. (INTS) had $14.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Intensity Therapeutics, Inc. spend on research and development?
Intensity Therapeutics, Inc. (INTS) invested $6.8M in research and development during fiscal year 2025.
What is Intensity Therapeutics, Inc.'s current ratio?
Intensity Therapeutics, Inc. (INTS) had a current ratio of 5.92 as of fiscal year 2025, which is generally considered healthy.
What is Intensity Therapeutics, Inc.'s debt-to-equity ratio?
Intensity Therapeutics, Inc. (INTS) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Intensity Therapeutics, Inc.'s return on assets (ROA)?
Intensity Therapeutics, Inc. (INTS) had a return on assets of -82.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Intensity Therapeutics, Inc.'s P/E ratio?
Intensity Therapeutics, Inc. (INTS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $11.3M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Intensity Therapeutics, Inc.'s price-to-sales ratio?
Intensity Therapeutics, Inc. (INTS) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $11.3M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Intensity Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Intensity Therapeutics, Inc. (INTS) held $11.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $9.2M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Intensity Therapeutics, Inc.'s Piotroski F-Score?
Intensity Therapeutics, Inc. (INTS) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Intensity Therapeutics, Inc.'s earnings high quality?
Intensity Therapeutics, Inc. (INTS) reported a net loss of $11.6M while operations used $9.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.